{"id":207895,"date":"2017-07-26T01:27:29","date_gmt":"2017-07-26T05:27:29","guid":{"rendered":"http:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/trivascular-technologies-triv-stryker-corporation-syk-critical-review-stock-observer\/"},"modified":"2017-07-26T01:27:29","modified_gmt":"2017-07-26T05:27:29","slug":"trivascular-technologies-triv-stryker-corporation-syk-critical-review-stock-observer","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/neurotechnology\/trivascular-technologies-triv-stryker-corporation-syk-critical-review-stock-observer\/","title":{"rendered":"Trivascular Technologies (TRIV) &amp; Stryker Corporation (SYK) Critical Review &#8211; Stock Observer"},"content":{"rendered":"<p><p>    Stryker Corporation (NYSE: SYK) and Trivascular Technologies    (NASDAQ:TRIV) are both medical companies, but which is the    superior business? We will compare the two businesses based on    the strength of their risk, institutional ownership, dividends,    valuation, earnings, profitabiliy and analyst recommendations.  <\/p>\n<p>    Analyst Ratings  <\/p>\n<p>    This is a breakdown of current ratings for Stryker Corporation    and Trivascular Technologies, as provided by MarketBeat.  <\/p>\n<p>    Stryker Corporation presently has a consensus price target of    $139.21, suggesting a potential downside of 4.69%. Given    Stryker Corporations higher probable upside, equities research    analysts plainly believe Stryker Corporation is more favorable    than Trivascular Technologies.  <\/p>\n<p>    Dividends  <\/p>\n<p>    Stryker Corporation pays an annual dividend of $1.70 per share    and has a dividend yield of 1.2%. Trivascular Technologies does    not pay a dividend. Stryker Corporation pays out 38.2% of its    earnings in the form of a dividend. Trivascular Technologies    has raised its dividend for 6 consecutive years.  <\/p>\n<p>    Insider and Institutional Ownership  <\/p>\n<p>    74.3% of Stryker Corporation shares are owned by institutional    investors. 7.4% of Stryker Corporation shares are owned by    company insiders. Strong institutional ownership is an    indication that large money managers, endowments and hedge    funds believe a stock is poised for long-term growth.  <\/p>\n<p>    Profitability  <\/p>\n<p>    This table compares Stryker Corporation and Trivascular    Technologies net margins, return on equity and return on    assets.  <\/p>\n<p>    Earnings & Valuation  <\/p>\n<p>    This table compares Stryker Corporation and Trivascular    Technologies gross revenue, earnings per share and valuation.  <\/p>\n<p>    Stryker Corporation has higher revenue and earnings than    Trivascular Technologies.  <\/p>\n<p>    Summary  <\/p>\n<p>    Stryker Corporation beats Trivascular Technologies on 9 of the    11 factors compared between the two stocks.  <\/p>\n<p>    About Stryker Corporation  <\/p>\n<p>    Stryker Corporation is a medical technology    company. The Company offers a range of medical technologies,    including orthopedic, medical and surgical, and neurotechnology    and spine products. The Companys segments include    Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate    and Other. The Orthopaedics segment includes reconstructive    (hip and knee) and trauma implant systems and other related    products. The MedSurg segment includes surgical equipment and    surgical navigation systems; endoscopic and communications    systems; patient handling, emergency medical equipment,    intensive care disposable products; reprocessed and    remanufactured medical devices, and other related products. The    Neurotechnology and Spine segment includes neurovascular    products, spinal implant systems and other related products.    The Companys products include implants, which are used in    joint replacement and trauma surgeries, and other products that    are used in a range of medical specialties.  <\/p>\n<p>    About Trivascular Technologies  <\/p>\n<p>    Trivascular    Technologies, Inc. is a medical device company developing and    commercializing technologies to advance minimally invasive    treatment of abdominal aortic aneurysms (AAA). The Ovation    System, the Companys solution for the treatment of AAA through    minimally invasive endovascular aortic repair, or EVAR, is a    stent graft platform, providing an alternative to conventional    devices. It is designed to specifically address many of the    limitations associated with conventional EVAR devices and    expand the pool of patients eligible for EVAR. The Company is    developing Ovation iX iliac limbs for use with both its Ovation    Prime and its Ovation iX and Alto aortic bodies, which are in    development. Trivascular is developing Ovation iX aortic bodies    for use with both its Ovation Prime and its Ovation iX iliac    limbs. The Company is developing an aortic body that together    with the iliac limbs makes up the Ovation Alto stent graft.      <\/p>\n<p>    Receive News & Ratings for Stryker Corporation    Daily - Enter your email address below to receive a    concise daily summary of the latest news and analysts' ratings    for Stryker Corporation and related companies with     MarketBeat.com's FREE daily email newsletter.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Read the original: <\/p>\n<p><a target=\"_blank\" rel=\"nofollow\" href=\"https:\/\/www.thestockobserver.com\/2017\/07\/25\/trivascular-technologies-triv-stryker-corporation-syk-head-to-head-contrast-updated-updated-updated.html\" title=\"Trivascular Technologies (TRIV) &amp; Stryker Corporation (SYK) Critical Review - Stock Observer\">Trivascular Technologies (TRIV) &amp; Stryker Corporation (SYK) Critical Review - Stock Observer<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Stryker Corporation (NYSE: SYK) and Trivascular Technologies (NASDAQ:TRIV) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, dividends, valuation, earnings, profitabiliy and analyst recommendations <a href=\"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/neurotechnology\/trivascular-technologies-triv-stryker-corporation-syk-critical-review-stock-observer\/\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[187755],"tags":[],"class_list":["post-207895","post","type-post","status-publish","format-standard","hentry","category-neurotechnology"],"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/207895"}],"collection":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/comments?post=207895"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/207895\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/media?parent=207895"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/categories?post=207895"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/tags?post=207895"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}